r.rotation.to⌕ Search stocks, people, sectors
Following this device: dark.
Request a free account

Follow the people · Insider

SN

Seshadri Neervannan

Insider · Chief Operating Officer · TARS

Seshadri Neervannan files insider transactions with the SEC as a chief operating officer of Tarsus Pharmaceuticals. We hold 6 disclosed purchases and sales filed since 8 January 2021, 1 of them in the last 90 days.

  • Files forTARS
  • Disclosed buys and sells6 in all, 1 in the last 90 days
  • Last disclosure9 September 2026

Positions held

1 post we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 7 January 2021 — 4 September 2026Chief Operating Officer · Tarsus Pharmaceuticals 55 Form 4 lines · source: SEC Form 4

Every transaction

55 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing
55 of 55 shown
4 Sep 20269 Sep 2026SEC Form 45 dsold on the open marketTarsus Pharmaceuticals4,564 sharesdown −8.8%up +0.0%
20 Mar 202624 Mar 2026SEC Form 44 dsold on the open marketTarsus Pharmaceuticals2,989 sharesup +28.3%up +31.1%
20 Mar 202624 Mar 2026SEC Form 44 dsold on the open marketTarsus Pharmaceuticals2,989 sharesup +28.3%up +31.1%
19 Mar 202619 Mar 2026SEC Form 40 dsold on the open marketTarsus Pharmaceuticals4,589 sharesup +24.0%up +24.0%
19 Mar 202619 Mar 2026SEC Form 40 dsold on the open marketTarsus Pharmaceuticals4,589 sharesup +24.0%up +24.0%
18 Mar 202619 Mar 2026SEC Form 41 dsold on the open marketTarsus Pharmaceuticals3,610 sharesup +21.3%up +24.0%
18 Mar 202619 Mar 2026SEC Form 41 dsold on the open marketTarsus Pharmaceuticals3,610 sharesup +21.3%up +24.0%
17 Mar 202619 Mar 2026SEC Form 42 dsold on the open marketTarsus Pharmaceuticals3,125 sharesup +18.6%up +24.0%
17 Mar 202619 Mar 2026SEC Form 42 dsold on the open marketTarsus Pharmaceuticals3,125 sharesup +18.6%up +24.0%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticals26,287 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative5,097 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative8,148 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative5,097 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative8,148 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative8,020 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative5,022 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative8,020 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative5,022 sharesup +21.8%up +18.6%
15 Mar 202617 Mar 2026SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticals26,287 sharesup +21.8%up +18.6%
5 Mar 20269 Mar 2026SEC Form 44 dwas grantednot a tradeTarsus Pharmaceuticalsderivative27,310 sharesup +10.5%up +11.1%
5 Mar 20269 Mar 2026SEC Form 44 dwas grantednot a tradeTarsus Pharmaceuticalsderivative17,161 sharesup +10.5%up +11.1%
5 Mar 20269 Mar 2026SEC Form 44 dwas grantednot a tradeTarsus Pharmaceuticalsderivative27,310 sharesup +10.5%up +11.1%
5 Mar 20269 Mar 2026SEC Form 44 dwas grantednot a tradeTarsus Pharmaceuticalsderivative17,161 sharesup +10.5%up +11.1%
4 Mar 20265 Mar 2026SEC Form 41 dsold on the open marketTarsus Pharmaceuticals8,366 sharesup +8.6%up +10.5%
4 Mar 20265 Mar 2026SEC Form 41 dsold on the open marketTarsus Pharmaceuticals8,366 sharesup +8.6%up +10.5%
16 Dec 202518 Dec 2025SEC Form 42 dgave awaynot a tradeTarsus Pharmaceuticals950 sharesup +5.7%up +6.8%
16 Dec 202518 Dec 2025SEC Form 42 dgave awaynot a tradeTarsus Pharmaceuticals475 sharesup +5.7%up +6.8%
20 Mar 202520 Mar 2025SEC Form 40 dsold on the open marketTarsus Pharmaceuticals2,435 sharesup +65.8%up +65.8%
19 Mar 202520 Mar 2025SEC Form 41 dsold on the open marketTarsus Pharmaceuticals2,543 sharesup +67.0%up +65.8%
18 Mar 202520 Mar 2025SEC Form 42 dsold on the open marketTarsus Pharmaceuticals2,605 sharesup +79.3%up +65.8%
15 Mar 202518 Mar 2025SEC Form 43 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative5,097 sharesup +72.1%up +79.3%
15 Mar 202518 Mar 2025SEC Form 43 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative8,148 sharesup +72.1%up +79.3%
15 Mar 202518 Mar 2025SEC Form 43 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative8,019 sharesup +72.1%up +79.3%
15 Mar 202518 Mar 2025SEC Form 43 dexercised options overnot a tradeTarsus Pharmaceuticals21,264 sharesup +72.1%up +79.3%
5 Mar 20257 Mar 2025SEC Form 42 dwas grantednot a tradeTarsus Pharmaceuticalsderivative30,628 sharesup +85.8%up +78.1%
5 Mar 20257 Mar 2025SEC Form 42 dwas grantednot a tradeTarsus Pharmaceuticalsderivative20,089 sharesup +85.8%up +78.1%
18 Mar 202419 Mar 2024SEC Form 41 dsold on the open marketTarsus Pharmaceuticals4,879 sharesup +170.4%up +162.6%
15 Mar 202419 Mar 2024SEC Form 44 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative5,097 sharesup +162.1%up +162.6%
15 Mar 202419 Mar 2024SEC Form 44 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative8,148 sharesup +162.1%up +162.6%
15 Mar 202419 Mar 2024SEC Form 44 dexercised options overnot a tradeTarsus Pharmaceuticals13,245 sharesup +162.1%up +162.6%
7 Mar 202411 Mar 2024SEC Form 44 dwas grantednot a tradeTarsus Pharmaceuticalsderivative47,500 sharesup +133.2%up +171.4%
7 Mar 202411 Mar 2024SEC Form 44 dwas grantednot a tradeTarsus Pharmaceuticalsderivative32,079 sharesup +133.2%up +171.4%
23 Mar 202323 Mar 2023SEC Form 40 dsold on the open marketTarsus Pharmaceuticals390 sharesup +581.8%up +581.8%
22 Mar 202323 Mar 2023SEC Form 41 dsold on the open marketTarsus Pharmaceuticals379 sharesup +587.5%up +581.8%
21 Mar 202323 Mar 2023SEC Form 42 dsold on the open marketTarsus Pharmaceuticals372 sharesup +541.6%up +581.8%
20 Mar 202321 Mar 2023SEC Form 41 dsold on the open marketTarsus Pharmaceuticals380 sharesup +534.3%up +541.6%
17 Mar 202321 Mar 2023SEC Form 44 dsold on the open marketTarsus Pharmaceuticals360 sharesup +549.2%up +541.6%
16 Mar 202317 Mar 2023SEC Form 41 dsold on the open marketTarsus Pharmaceuticals357 sharesup +516.8%up +549.2%
15 Mar 202317 Mar 2023SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticalsderivative5,097 sharesup +502.4%up +549.2%
15 Mar 202317 Mar 2023SEC Form 42 dexercised options overnot a tradeTarsus Pharmaceuticals5,097 sharesup +502.4%up +549.2%
8 Mar 202310 Mar 2023SEC Form 42 dwas grantednot a tradeTarsus Pharmaceuticalsderivative48,116 sharesup +451.8%up +480.4%
8 Mar 202310 Mar 2023SEC Form 42 dwas grantednot a tradeTarsus Pharmaceuticalsderivative32,592 sharesup +451.8%up +480.4%
9 Mar 202211 Mar 2022SEC Form 42 dwas grantednot a tradeTarsus Pharmaceuticalsderivative69,498 sharesup +322.5%up +344.3%
9 Mar 202211 Mar 2022SEC Form 42 dwas grantednot a tradeTarsus Pharmaceuticalsderivative20,388 sharesup +322.5%up +344.3%
7 Jan 20218 Jan 2021SEC Form 41 dwas grantednot a tradeTarsus Pharmaceuticalsderivative61,499 sharesup +75.2%up +84.8%

Both percentages are the stock’s move, not Seshadri Neervannan’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 9 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 55 of the 55 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.